Morgan Stanley lowered the firm’s price target on ShockWave Medical to $223 from $284 and keeps an Overweight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SWAV:
- Needham medtech analysts hold analyst/industry conference call
- Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference
- ShockWave Medical announces new data on one-year outcomes with IVL
- New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men
- ShockWave Medical price target lowered to $260 from $265 at Needham